Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Antwerp University Hospital (UZA)

Status and phase

Completed

Phase 3

Conditions

Chronic Obstructive Pulmonary Disease

Treatments

Drug: Inuvair

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01204034

PML-DOC-1003

2010-019864-36 (EudraCT Number)

Details and patient eligibility

About

The objective of this study is to evaluate the effect of the combination of formoterol and beclometasone dipropionate on central and peripheral airway dimensions in COPD patients using Computational Fluid Dynamics (CFD). Further more, the effect of this combination therapy on lung function (spirometry, body plethysmography), the BODE index, COPD assessment test (CAT) and Borg CR10 scale will be assessed and the safety will be evaluated.

Enrollment

29 patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with documented COPD based on the following criteria:

Smoking history of at least 10 pack-years Decreased Tiffeneau index: FEV1/FVC < 0.70

Male or female patients aged ≥ 40 years
Patients should be treated according to the 'Global initiative for chronic Obstructive Lung Disease' (GOLD) guidelines
Patients who present
Moderate COPD with an FEV1 between 50 and 80% of predicted GOLD 2)
Severe COPD with an FEV1 between 30 and 50% of predicted (GOLD 3)
Very severe COPD with an FEV1 lower than 30% of predicted (GOLD 4)
Patients will be maintained on stable respiratory medications for 6 weeks prior to screening
Patients with a co-operative attitude and ability to be trained to correctly use the pMDI
Written informed consent obtained

Exclusion criteria

Pregnant or lactating females or females at risk of pregnancy
Unstable patients who developed an exacerbation during the last 4 weeks
Inability to carry out pulmonary function testing
Diagnosis of asthma as defined by the current 'Global Initiative for Asthma' (GINA) guidelines
Patients with an uncontrolled disease or any condition that might, in the judgement of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study
Patients with a QTc interval (Bazett's formula) at the screening visit electrocardiogram (ECG) test >450 msec
Cancer or any other chronic disease with poor prognosis and /or affecting patient status
History of alcohol or drug abuse
Allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients
Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study
Patients who received any investigational new drug within the last 4 weeks prior to the screening visit
Patients treated with any non-permitted concomitant medication